Effect of tumor size on monoclonal antibody uptake in a metastatic model

✍ Scribed by Kazuhiko Yoshida; Michel L. Rivoire; Chaitanya R. Divgi; Donna Niedzwiechi; Alfred M. Cohen; Elin R. Sigurdson

• Publisher: John Wiley and Sons
• Year: 1992
• Tongue: English
• Weight: 363 KB
• Volume: 49
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930490409

✦ Synopsis

We studied the effect of tumor size on monoclonal antibody (mAb) in a murine hepatic model. Intrasplenic injection of HT-29 LMM metastatic human colon cancer cell line reproducibly results in hepatic metastases formation in congenitally athymic mice. HT-29-15, a murine mAb of the IgGl class reactive with the HT-29 LMM cell line, and BL-3, an isotypematched control mAb, were labeled with iodine 125. Labeled mAbs were injected intravenously into mice with hepatic metastases. Animals were sacrificed on day 5 , and tumor and normal tissue weighed and counted. Specific mAb uptake (percent injected dose per gram, %ID/g) by hepatic metastases (5.16 2 3.96) was significantly greater than nonspecific uptake (1.41 2 0.42) (P < 0.001). %ID/g of tumor was dependent upon the mAb used, and was independent of tumor weight; consequently, a linear correlation between tumor weight and total uptake (%ID) for specific mAb (r = 0.88, P < 0.0001) and nonspecific mAb (r = 0.99, P < 0.0001) administration was demonstrated. We have shown both specific and nonspecific mAb uptake per gram of tumor to be a constant for the given mAb/tumor system and with uptake of mAb to be linearly related to tumor weight.